The Cooper Companies, Inc. $COO Stock Position Increased by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB grew its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 38.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 327,500 shares of the medical device company’s stock after purchasing an additional 90,500 shares during the period. Cooper Companies comprises about 2.5% of Rhenman & Partners Asset Management AB’s portfolio, making the stock its 6th biggest position. Rhenman & Partners Asset Management AB owned about 0.17% of Cooper Companies worth $26,842,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Root Financial Partners LLC increased its stake in Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares during the period. Bell Investment Advisors Inc increased its stake in Cooper Companies by 106.3% during the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock worth $29,000 after purchasing an additional 219 shares during the period. CYBER HORNET ETFs LLC purchased a new stake in Cooper Companies during the second quarter worth about $36,000. True Wealth Design LLC increased its stake in Cooper Companies by 484.8% during the fourth quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock worth $38,000 after purchasing an additional 383 shares during the period. Finally, Cromwell Holdings LLC increased its stake in Cooper Companies by 128.8% during the fourth quarter. Cromwell Holdings LLC now owns 485 shares of the medical device company’s stock worth $40,000 after purchasing an additional 273 shares during the period. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Cooper Companies Stock Performance

Shares of COO opened at $67.88 on Friday. The stock has a 50 day moving average price of $64.79 and a 200 day moving average price of $74.35. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $13.24 billion, a price-to-earnings ratio of 57.53, a price-to-earnings-growth ratio of 1.77 and a beta of 0.87. The Cooper Companies, Inc. has a 52-week low of $58.89 and a 52-week high of $89.83.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.11. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The firm’s quarterly revenue was up 7.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.96 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Research analysts predict that The Cooper Companies, Inc. will post 4.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on COO shares. BNP Paribas Exane cut their price target on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a research note on Monday, June 8th. JPMorgan Chase & Co. cut their price target on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a research note on Friday, June 5th. Robert W. Baird cut their price target on shares of Cooper Companies from $98.00 to $85.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Wall Street Zen lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Barclays upped their target price on shares of Cooper Companies from $98.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cooper Companies has a consensus rating of “Hold” and a consensus price target of $82.64.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.